The introduction of the LHRH agonist, Goserelin (Zoladex) into clinical practice

Endocrine-Related Cancer

Volumn 4, Issue 3, 1997, Pages 229-232

  Blamey, R W ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; METHOTREXATE; TAMOXIFEN;

BREAST CANCER; CLINICAL TRIAL; FEMALE; HUMAN; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030749518     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0040229     Document Type: Short Survey

References (11)

1. Beatson GT 1896 On treatment of inoperable cases of carcinoma of the mamma. Lancet ii 104-107 and 162-165.
2. Blamey RW, Jonat W, Kaufmann M, Bianco AE & Namer M 1992 Goserelin depot in the treatment of premenopausal advanced breast cancer. European Journal of Cancer 28A 810-814.
3. Boccardo F, Rubagotti A, Perrotta A, Amoroso D, Balestrero M, De Matteis A, Zola P, Sismondi P, Francini G, Petrioli R et al. 1994 Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer results of a multicentric Italian study. Annals of Oncology 5 337-342.
4. Dixon AR, Nicholson RI & Blarney RW 1991 Combined LHRH agonist ('Zoladex') and tamoxifen therapy in pre-menopausal advanced breast cancer: current controversies in the treatment of breast cancer. 1st Nottingham International Breast Cancer Meeting, 22-28 September 1990. The Nottingham Proceedings 2 41-49.
5. Early Breast Cancer Trialists' Collaborative Group 1996 Ovarian ablation in early breast cancer - overview of the randomized trials. Lancet 348 1189-1196.
6. Henderson IC 1991 Endocrine therapy of metastatic breast cancer. Table 22-21. In Breast Disease, pp 559-603. Eds JR Harris, S Hellman, IC Henderson & DW Kinne. Philadelphia: JB Lippincott Co.
7. Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Jänicke F, Njordenskold B, Forbes JF & Kolvenbag GJCM 1995 A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. European Journal of Cancer 31A 137-142.
8. Klijn JGM, Beex L, Mauriac L, van Zijl J, Veyret C, Wildiers J, Jassem J, Burghouts J, Piccart M & Hoctin-Boes G 1996 Addition of an LHRH-agonist to Tamoxifen (TAM) improves survival in premenopausal patients with metastatic breast cancer: detailed analysis of EORTC Study 10881. Annals of Oncology 7 19 (Abstract).
9. Meakin JW, Hayward JL, Panzarella T, Allt WEC, Beale FA, Bulbrook RD, Bush RS, Clark RM, Fitzpatrick PJ, Hawkins NV, Jenkin RDT, Pringle JF & Rider WF 1996 Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Research and Treatment 37 11-19.
10. Williams MR, Walker KJ, Turkes A, Blarney RW & Nicholson RI 1986 The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. British Journal of Cancer 53 629-636.
11. Williamson K, Robertson JFR, Ellis IO, Elston CW, Nicholson RI & Blamey RW 1988 Effect of LHRH agonist, Zoladex, on ovarian histology. British Journal of Surgery 75 595-596.